Can Angioimmunoblastic T cell lymphoma (AITL) be cured? The answer to this question depends on a variety of factors, such as the stage of the lymphoma, the patient’s overall health, and the treatments used.
In general, AITL is considered to be a type of indolent (slow-growing) lymphoma, and it can sometimes be cured with aggressive therapy. The most common treatment is combination chemotherapy, often in conjunction with radiation therapy. This treatment is usually successful in inducing a complete remission in up to 80 percent of patients. However, even with successful treatment, many patients will experience a relapse within five years of their initial diagnosis.
In addition to chemotherapy and radiation therapy, some patients with AITL may benefit from targeted therapies, such as monoclonal antibodies. These therapies can be used to target specific molecules on T cells, which can then be destroyed. This can help to reduce the number of cancerous cells and improve the prognosis.
For patients who do not respond to standard treatments or who experience a relapse, stem cell transplantation may be an option. This involves replacing the patient’s damaged or cancerous bone marrow with healthy stem cells from a donor. This can reduce the risk of relapse and improve the patient’s chances of survival.
Overall, while AITL can be cured with aggressive and targeted therapies, the success of treatment depends on the stage of the lymphoma and the patient’s overall health. It is important to speak with a healthcare professional to determine the best course of treatment for each individual case.